Orajel joins C&D
This article was originally published in The Tan Sheet
Church & Dwight adds Orajel to its brand portfolio as the firm completes its acquisition of the Del OTC pharmaceutical business from Coty Inc, according to a July 7 release. C&D paid $380 million cash at closing while the purchase price includes a $250 million addition to its bank credit facility and available cash. The Princeton, N.J.-based firm expects the acquisition, announced in April 2008, to have a "neutral impact on 2008 earnings per share due primarily to one-time integration costs and the step-up of inventory" (1"The Tan Sheet" April 7, 2008, p. 3)...
You may also be interested in...
Church & Dwight agreed to acquire Del Pharmaceuticals' OTC brands, including the Orajel topical analgesic line, for $380 million in cash from Coty, Inc., the firm said April 1
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”
A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.